Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
MYC rearrangement + BCL2 rearrangement
i
Other names:
MYC, bHLHe39, c-Myc, MYCC, V-myc avian myelocytomatosis viral oncogene homolog, BCL2, Bcl-2, PPP1R50, B-cell CLL/lymphoma 2
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
4609
;
596
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
BCL2/BCL2L1 ratio elevation (3)
BCL2 rearrangement + MYC amplification (2)
HR positive + MYC amplification (2)
MYC amplification + ALK F1174L (2)
MYC expression + MYC rearrangement (2)
MYC overexpression + IDH1 mutation (2)
MYC overexpression + IDH2 mutation (2)
MYC rearrangement + LDH elevation (2)
BCL2/MCL1 ratio elevation (2)
ALK fusion + MYC amplification + CCND1 deletion + FGFR3 deletion (1)
ALK positive + MYC amplification + CCND1 deletion (1)
EGFR T790M + MYC amplification (1)
HER-2 positive + MYC amplification (1)
HR positive + MYC mutation (1)
IDH1 mutation + MYC amplification + MAPRE1 overexpression (1)
IDH2 mutation + MYC amplification + MAPRE1 overexpression (1)
KIF5B-RET fusion + TP53 H193R + MYC amplification (1)
MYC amplification + BCL2 amplification + TNFRSF8 expression (1)
MYC mutation + ER positive (1)
miR-17-HG deletion + MYC positive (1)
BCL2 elevation + IGH elevation (1)
BCL2 fusion + EZH2 mutation (1)
Chr t(11;14) + BCL2 : BCL2L1 ratio elevation (1)
Chr t(11;14) + BCL2 overexpression (1)
PTEN deletion + BCL2 translocation (1)
BCL2/BAX ratio elevation (0)
BCL2/BCL2L1 ratio elevation (3)
BCL2 rearrangement + MYC amplification (2)
HR positive + MYC amplification (2)
MYC amplification + ALK F1174L (2)
MYC expression + MYC rearrangement (2)
MYC overexpression + IDH1 mutation (2)
MYC overexpression + IDH2 mutation (2)
MYC rearrangement + LDH elevation (2)
BCL2/MCL1 ratio elevation (2)
ALK fusion + MYC amplification + CCND1 deletion + FGFR3 deletion (1)
ALK positive + MYC amplification + CCND1 deletion (1)
EGFR T790M + MYC amplification (1)
HER-2 positive + MYC amplification (1)
HR positive + MYC mutation (1)
IDH1 mutation + MYC amplification + MAPRE1 overexpression (1)
IDH2 mutation + MYC amplification + MAPRE1 overexpression (1)
KIF5B-RET fusion + TP53 H193R + MYC amplification (1)
MYC amplification + BCL2 amplification + TNFRSF8 expression (1)
MYC mutation + ER positive (1)
miR-17-HG deletion + MYC positive (1)
BCL2 elevation + IGH elevation (1)
BCL2 fusion + EZH2 mutation (1)
Chr t(11;14) + BCL2 : BCL2L1 ratio elevation (1)
Chr t(11;14) + BCL2 overexpression (1)
PTEN deletion + BCL2 translocation (1)
BCL2/BAX ratio elevation (0)
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
lisocabtagene maraleucel
Sensitive: A2 - Guideline
lisocabtagene maraleucel
Sensitive
:
A2
lisocabtagene maraleucel
Sensitive: A2 - Guideline
lisocabtagene maraleucel
Sensitive
:
A2
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
lenalidomide
Sensitive: B - Late Trials
lenalidomide
Sensitive
:
B
lenalidomide
Sensitive: B - Late Trials
lenalidomide
Sensitive
:
B
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
cytarabine + methotrexate
Resistant: C3 – Early Trials
cytarabine + methotrexate
Resistant
:
C3
cytarabine + methotrexate
Resistant: C3 – Early Trials
cytarabine + methotrexate
Resistant
:
C3
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
rituximab
Resistant: C3 – Early Trials
rituximab
Resistant
:
C3
rituximab
Resistant: C3 – Early Trials
rituximab
Resistant
:
C3
MYC rearrangement + BCL2 rearrangement
Lymphoma
MYC rearrangement + BCL2 rearrangement
Lymphoma
lisocabtagene maraleucel
Sensitive: C3 – Early Trials
lisocabtagene maraleucel
Sensitive
:
C3
lisocabtagene maraleucel
Sensitive: C3 – Early Trials
lisocabtagene maraleucel
Sensitive
:
C3
MYC rearrangement + BCL2 rearrangement
Non-Hodgkin’s Lymphoma
MYC rearrangement + BCL2 rearrangement
Non-Hodgkin’s Lymphoma
ibrutinib
Sensitive: C3 – Early Trials
ibrutinib
Sensitive
:
C3
ibrutinib
Sensitive: C3 – Early Trials
ibrutinib
Sensitive
:
C3
MYC rearrangement + BCL2 rearrangement
Follicular Lymphoma
MYC rearrangement + BCL2 rearrangement
Follicular Lymphoma
Sensitive: C3 – Early Trials
Sensitive
:
C3
Sensitive: C3 – Early Trials
Sensitive
:
C3
MYC rearrangement + BCL2 rearrangement
Follicular Lymphoma
MYC rearrangement + BCL2 rearrangement
Follicular Lymphoma
Sensitive: C3 – Early Trials
Sensitive
:
C3
Sensitive: C3 – Early Trials
Sensitive
:
C3
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
lenalidomide + zanubrutinib
Sensitive: C3 – Early Trials
lenalidomide + zanubrutinib
Sensitive
:
C3
lenalidomide + zanubrutinib
Sensitive: C3 – Early Trials
lenalidomide + zanubrutinib
Sensitive
:
C3
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
loncastuximab tesirine-lpyl
Sensitive: C3 – Early Trials
loncastuximab tesirine-lpyl
Sensitive
:
C3
loncastuximab tesirine-lpyl
Sensitive: C3 – Early Trials
loncastuximab tesirine-lpyl
Sensitive
:
C3
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
Sensitive: C3 – Early Trials
Sensitive
:
C3
Sensitive: C3 – Early Trials
Sensitive
:
C3
MYC rearrangement + BCL2 rearrangement
Lymphoma
MYC rearrangement + BCL2 rearrangement
Lymphoma
AR160
Sensitive: C3 – Early Trials
AR160
Sensitive
:
C3
AR160
Sensitive: C3 – Early Trials
AR160
Sensitive
:
C3
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
axicabtagene ciloleucel
Sensitive: C3 – Early Trials
axicabtagene ciloleucel
Sensitive
:
C3
axicabtagene ciloleucel
Sensitive: C3 – Early Trials
axicabtagene ciloleucel
Sensitive
:
C3
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
IACS-010759
Sensitive: D – Preclinical
IACS-010759
Sensitive
:
D
IACS-010759
Sensitive: D – Preclinical
IACS-010759
Sensitive
:
D
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
ibrutinib
Resistant: D – Preclinical
ibrutinib
Resistant
:
D
ibrutinib
Resistant: D – Preclinical
ibrutinib
Resistant
:
D
MYC rearrangement + BCL2 rearrangement
Non-Hodgkin’s Lymphoma
MYC rearrangement + BCL2 rearrangement
Non-Hodgkin’s Lymphoma
ibrutinib + alemtuzumab
Sensitive: D – Preclinical
ibrutinib + alemtuzumab
Sensitive
:
D
ibrutinib + alemtuzumab
Sensitive: D – Preclinical
ibrutinib + alemtuzumab
Sensitive
:
D
MYC rearrangement + BCL2 rearrangement
Lymphoma
MYC rearrangement + BCL2 rearrangement
Lymphoma
HZX-02-059
Sensitive: D – Preclinical
HZX-02-059
Sensitive
:
D
HZX-02-059
Sensitive: D – Preclinical
HZX-02-059
Sensitive
:
D
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
venetoclax
Sensitive: D – Preclinical
venetoclax
Sensitive
:
D
venetoclax
Sensitive: D – Preclinical
venetoclax
Sensitive
:
D
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
copanlisib
Sensitive: D – Preclinical
copanlisib
Sensitive
:
D
copanlisib
Sensitive: D – Preclinical
copanlisib
Sensitive
:
D
MYC rearrangement + BCL2 rearrangement
Lymphoma
MYC rearrangement + BCL2 rearrangement
Lymphoma
venetoclax + DUP 785
Sensitive: D – Preclinical
venetoclax + DUP 785
Sensitive
:
D
venetoclax + DUP 785
Sensitive: D – Preclinical
venetoclax + DUP 785
Sensitive
:
D
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
BTM-3566
Sensitive: D – Preclinical
BTM-3566
Sensitive
:
D
BTM-3566
Sensitive: D – Preclinical
BTM-3566
Sensitive
:
D
MYC rearrangement + BCL2 rearrangement
Lymphoma
MYC rearrangement + BCL2 rearrangement
Lymphoma
SGN-CD19B
Sensitive: D – Preclinical
SGN-CD19B
Sensitive
:
D
SGN-CD19B
Sensitive: D – Preclinical
SGN-CD19B
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login